Stockholm, Sweden – September 30, 2010. Ulf Björklund has been appointed new Chief Executive Officer (CEO) of Aprea. Ulf Björklund is today the CEO of OxyPharma. He will take up the position in October; the previous CEO Thomas Uhlin has in September left Aprea to join the Swedish Medical Products Agency. Ulf Björklund has a long extensive experience from the pharmaceutical industry, including small start up companies and big pharma. Prior to joining OxyPharma 2002 Ulf spent more then 15 years with Pharmacia. Aprea is now in the end of a Phase I study with their candidate drug APR-246 and is planning to start a Phase II study during the fall 2011.
“We are very pleased with the recruitment of Ulf Björklund as CEO at Aprea. At the same time we thank Thomas Uhlin for his valuable work at Aprea during the last three years” says Wenche Rolfsen, Chairman of the board, Aprea. Ulf has an outstanding experience in clinical drug development and has worked with different types of collaborations and has good experience from exit processes.
For more information, please contact:
Wenche Rolfsen, Chairman of the board, Aprea AB
Telephone: +46 (0)733319156
Ulf Björklund, CEO, Aprea AB
Telephone: +46 (0)706670440
About Aprea AB
Aprea AB is a Swedish biotech company founded in 2003 and based on research performed at the Karolinska Institutet, Stockholm, Sweden. The company focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea AB is currently initiating the commercialization process and seeking partners. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Industrifonden, Östersjöstiftelsen and Praktikerinvest.